Compare PKE & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | AVIR |
|---|---|---|
| Founded | 1954 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.4M | 429.1M |
| IPO Year | 1994 | 2020 |
| Metric | PKE | AVIR |
|---|---|---|
| Price | $29.96 | $5.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 197.0K | ★ 239.9K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 93.10 | 3.00 |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $174.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.25 | $2.78 |
| 52 Week High | $39.86 | $6.45 |
| Indicator | PKE | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 47.16 |
| Support Level | $23.29 | $5.09 |
| Resistance Level | $35.94 | $5.79 |
| Average True Range (ATR) | 1.08 | 0.23 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 30.91 | 23.53 |
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.